This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AstraZeneca Makes Major Commitment To Help Patients With Acute Coronary Syndrome Have BRILINTA (ticagrelor) Available In Their Local Communities

AstraZeneca (NYSE: AZN) today announced a new program with more than 26,000 national, regional and independent pharmacies to broaden stocking of BRILINTA ® (ticagrelor) tablets, greatly enhancing its retail availability in the United States. This new pharmacy program is another investment by AstraZeneca to help patients with acute coronary syndrome (ACS) and healthcare providers maintain continuity of care throughout the course of treatment. AstraZeneca is working with payers as well as pharmacies to assist patients in filling their prescriptions for BRILINTA in a timely manner once they leave the hospital.

Participating pharmacy chains in this unique program include Walmart, Rite Aid, Kmart, Sam’s Club, Publix, Kerr Drug, Wegmans, Giant Eagle, Tops Markets, Kinney Drug, Bartell Drug, Bi-Lo, and Winn-Dixie. These participating retail chains are not exclusive distributors and BRILINTA may be available at other retail pharmacy chains and independent pharmacies. For additional information, please call 1-888-512-7454 (1-888-51-BRILINTA).

“Our pharmacy program is one of many initiatives we have in place to help ensure that patients with ACS have widespread access to BRILINTA, an important medication indicated to reduce their risk for thrombotic cardiovascular events,” said James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, U.S., and Vice President for Global Medical Affairs at AstraZeneca. “When a treating physician prescribes BRILINTA, it is critical that their patients start and finish the entire course of treatment without unnecessary disruptions, particularly when transitioning from the hospital to home. We believe this program will truly help patients to get access to a medication that is now part of multiple guidelines' recommended treatment following an ACS event.”

“Our efforts to help improve continuity of care are important for patients prescribed BRILINTA and pharmacies are key partners for us,” said Suzanne Delaney, Executive Director, Commercial Brand Leader at AstraZeneca. “It’s gratifying for us to see such robust support from wholesalers, retailers and payers, indicating positive momentum in the market.”

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs